Clinical Trials Directory

Trials / Completed

CompletedNCT03882606

Implantation of SML in Patients With Dry Age-related Macular Degeneration and Myopic Maculopathy

Near Visual Acuity and Quality of Life Improvement After Implantation of the add-on Scharioth Macula Lens (SML, Medicontur) in Patients With Dry Age-related Macular Degeneration and Myopic Maculopathy

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
3 (actual)
Sponsor
Consorci Sanitari de Terrassa · Academic / Other
Sex
All
Age
50 Years
Healthy volunteers
Not accepted

Summary

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in developed countries among people over 50 years of age. Myopic maculopathy is also an important cause of irreversible vision loss. Reduced near visual acuity is still a major problem with all forms of AMD and myopic maculopathy. Various intraocular lenses for near vision (IOLs) or telescopic systems have been described but are not widely accepted and almost all solutions require phakic status of the eye and are implanted during cataract surgery. Therefore, these devices are not appropriated for pseudophakic AMD and myopic maculopathy patients. Scharioth Macula Lens (SML, Medicontur) is a magnifying intraocular lens for pseudophakic patients implanted in the ciliary sulcus in one eye of each patient. The implant has a bifocal optic, with a central 1.5mm diameter optical zone equivalent to +10D add and a peripheral zone optically neutral. The implantation of the add-on SML can improve the near visual acuity of pseudophakic patients with AMD and myopic maculopathy without impairing their distance visual acuity. The principal objective is to compare the near visual acuity, the far visual acuity and the self-reported vision health status before and after the SML implantation.

Detailed description

We present a prospective study of a cohort of patients with age-related macular degeneration and myopic maculopathy treated with SML implantation. The study was approved by the ethics committee at the Consorci Sanitari de Terassa (Barcelona, Spain). Patients will be examined for best corrected visual acuity prior to the surgery at 6 meter and for reading at 40cm (with a +2.5D) and 15 cm (with +6D). Improvement of the reading ability at 15 cm compared to 40 cm will predict the potential for vision improvement with the add on lens. The preoperative and postoperative assessment will include a full ophthalmological exam, visual acuity for distance and near, optical coherence tomography of the anterior chamber and of the macula, axial length and keratometry examination using biometry and VFQ25 questionnaire. Postoperative assessment will be performed at day 1, 1 week, 1, 3 and 6 months after surgery.

Conditions

Interventions

TypeNameDescription
DEVICEScharioth Macula Lens (SML, Medicontur)magnifying intraocular lens for pseudophakic patients implanted in the ciliary sulcus in one eye of each patient

Timeline

Start date
2019-05-22
Primary completion
2023-09-01
Completion
2023-09-01
First posted
2019-03-20
Last updated
2025-06-17

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT03882606. Inclusion in this directory is not an endorsement.